The role of Tim-3 blockade in the tumor immune microenvironment beyond T cells
Open Access
- 11 October 2024
- journal article
- research article
- Published by Elsevier in Pharmacological Research
- Vol. 209, 107458
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (82273949, 82330114)
This publication has 111 references indexed in Scilit:
- Atezolizumab and Platinum Plus Pemetrexed With or Without Bevacizumab for Metastatic Nonsquamous Non–Small Cell Lung CancerJAMA Oncology, 2024
- Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM‐3 antibody, in combination with decitabine or azacitidine in high‐ or very high‐risk myelodysplastic syndromesAmerican Journal of Hematology, 2023
- TIM-3 blockade in diffuse intrinsic pontine glioma models promotes tumor regression and antitumor immune memoryCancer Cell, 2023
- TIM-3 as a promising target for cancer immunotherapy in a wide range of tumorsCancer Immunology, Immunotherapy, 2023
- Immune checkpoint therapy—current perspectives and future directionsCell, 2023
- The TIM3/Gal9 signaling pathway: An emerging target for cancer immunotherapyCancer Letters, 2021
- Tumor-derived Exosomes Induced M2 Macrophage Polarization and Promoted the Metastasis of Osteosarcoma Cells Through Tim-3Archives of Medical Research, 2021
- Engineering Macrophages for Cancer Immunotherapy and Drug DeliveryAdvanced Materials, 2020
- TIM-3 Regulates CD103+ Dendritic Cell Function and Response to Chemotherapy in Breast CancerCancer Cell, 2018
- Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinomaHepatology, 2012